Get Quotes none
Home / Healthcare / Gene Therapy

Gene Therapy Market – By Type (Germ Line Gene Therapy and Somatic Gene Therapy), By Vector Type (Viral Vectors, Non-Viral Vectors, and Human Artificial Chromosome), and By Therapy Area (Cancer, Neurological Diseases, Infectious Diseases, Genetic Disorders, Rheumatoid Arthritis, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018 – 2027

  • Published On : Sep-2019
  • Total Pages : 110
  • Report Code : FAF-61
  • Base Year : 2018
  • Format :
REPORT SUMMARY
TABLE OF CONTENT
REQUEST SAMPLE

Industry Insights

The report covers the forecast and analysis of the gene therapy market on a global and regional level. The study provides historical data from 2015 to 2018 along with a forecast from 2019 to 2027 based on revenue (USD Million). The study includes drivers and restraints of the gene therapy market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the gene therapy market on a global level.

In order to give the users of this report a comprehensive view of the gene therapy market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.
The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new service launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the gene therapy market by segmenting the market based on the type, vector type, therapy area, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2027. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Gene therapy is utilized for treating neurodegenerative disorders like Alzheimer's, amyotrophic lateral sclerosis, and spinal muscular atrophy. Gene therapy is one of the key treatment kinds that will propel the market growth over the forecast period. Moreover, gene therapy also finds lucrative applications in precision medicine. In addition to this, a rise in the occurrence of cancer is prompting the demand to treat the disease through gene therapy.

Based on the type, the market can be segregated into Germ Line Gene Therapy and Somatic Gene Therapy. In terms of vector type, the gene therapy industry can be divided into Viral Vectors, Non-Viral Vectors, and Human Artificial Chromosome. On the basis of the therapy area, the market for gene therapy can be classified into Cancer, Neurological Diseases, Infectious Diseases, Genetic Disorders, Rheumatoid Arthritis, and Others.

The key players included in this market are Advanced Cell & Gene Therapy, Audentes Therapeutics, Benitec Biopharma, Biogen, Blubird Bio, Inc., Bristol-Myers Squibb Company, CHIESI Farmaceutici SPA, Eurofins Scientific, Geneta Science, Genzyme Corporation, Gilead, GlaxoSmithKline PLC, Human Stem Cells Institute, Novartis AG, Orchard Therapeutics, Pfizer Inc., Sangamo Therapeutics, Spark therapeutics, and Voyager Therapeutics.

Table of Content

  • CHAPTER 1. Executive Summary 23
  •  
  • CHAPTER 2. Gene Therapy market – Type Analysis 25
    • 2.1. Global Gene Therapy Market – Type Overview 25
    • 2.2. Global Gene Therapy Market Share, by Type, 2018 & 2025 (USD Million) 25
    • 2.3. Germ line Gene Therapy 27
    • 2.3.1. Global Germ line Gene Therapy Gene Therapy Market, 2016-2026 (USD Million) 27
    • 2.4. Somatic Gene Therapy 28
    • 2.4.1. Global Somatic Gene Therapy Gene Therapy Market, 2016-2026 (USD Million) 28
  •  
  • CHAPTER 3. Gene Therapy market – Vector Type Analysis 28
    • 3.1. Global Gene Therapy Market – Vector Type Overview 28
    • 3.2. Global Gene Therapy Market Share, by Vector Type, 2018 & 2025 (USD Million) 29
    • 3.3. Viral Vectors 30
    • 3.3.1. Global Viral Vectors Gene Therapy Market, 2016-2026 (USD Million) 30
    • 3.4. Non Viral Vectors 31
    • 3.4.1. Global Non Viral Vectors Gene Therapy Market, 2016-2026 (USD Million) 31
    • 3.5. Human Artificial Chromosome 32
    • 3.5.1. Global Human Artificial Chromosome Gene Therapy Market, 2016-2026 (USD Million) 32
  •  
  • CHAPTER 4. Gene Therapy market – Therapy Area Analysis 32
    • 4.1. Global Gene Therapy Market – Therapy Area Overview 32
    • 4.2. Global Gene Therapy Market Share, by Therapy Area, 2018 & 2025 (USD Million) 33
    • 4.3. Cancer 34
    • 4.3.1. Global Cancer Gene Therapy Market, 2016-2026 (USD Million) 34
    • 4.4. Infectious Diseases 35
    • 4.4.1. Global Infectious Diseases Gene Therapy Market, 2016-2026 (USD Million) 35
    • 4.5. Rheumatoid Arthritis 36
    • 4.5.1. Global Rheumatoid Arthritis Gene Therapy Market, 2016-2026 (USD Million) 36
    • 4.6. Genetic Disorders 37
    • 4.6.1. Global Genetic Disorders Gene Therapy Market, 2016-2026 (USD Million) 37
    • 4.7. Neurological Disorders 38
    • 4.7.1. Global Neurological Disorders Gene Therapy Market, 2016-2026 (USD Million) 38
    • 4.8. Others 39
    • 4.8.1. Global Others Gene Therapy Market, 2016-2026 (USD Million) 39
  •  
  • CHAPTER 5. Gene Therapy market – Regional Analysis 40
    • 5.1. Global Gene Therapy Market Regional Overview 40
    • 5.2. Global Gene Therapy Market Share, by Region, 2018 & 2025 (Value) 40
    • 5.3. North America 42
    • 5.3.1. North America Gene Therapy Market size and forecast, 2016-2026 42
    • 5.3.2. North America Gene Therapy Market, by Country, 2018 & 2025 (USD Million) 42
    • 5.3.3. North America Gene Therapy Market, by Type, 2016-2026 44
    • 5.3.3.1. North America Gene Therapy Market, by Type, 2016-2026 (USD Million) 44
    • 5.3.4. North America Gene Therapy Market, by Vector Type, 2016-2026 45
    • 5.3.4.1. North America Gene Therapy Market, by Vector Type, 2016-2026 (USD Million) 45
    • 5.3.5. North America Gene Therapy Market, by Therapy Area, 2016-2026 46
    • 5.3.5.1. North America Gene Therapy Market, by Therapy Area, 2016-2026 (USD Million) 46
    • 5.3.6. U.S. 47
    • 5.3.6.1. U.S. Market size and forecast, 2016-2026 (USD Million) 47
    • 5.3.7. Canada 48
    • 5.3.7.1. Canada Market size and forecast, 2016-2026 (USD Million) 48
    • 5.3.8. Mexico 49
    • 5.3.8.1. Mexico Market size and forecast, 2016-2026 (USD Million) 49
    • 5.4. Europe 50
    • 5.4.1. Europe Gene Therapy Market size and forecast, 2016-2026 50
    • 5.4.2. Europe Gene Therapy Market, by Country, 2018 & 2025 (USD Million) 50
    • 5.4.3. Europe Gene Therapy Market, by Type, 2016-2026 52
    • 5.4.3.1. Europe Gene Therapy Market, by Type, 2016-2026 (USD Million) 52
    • 5.4.4. Europe Gene Therapy Market, by Vector Type, 2016-2026 53
    • 5.4.4.1. Europe Gene Therapy Market, by Vector Type, 2016-2026 (USD Million) 53
    • 5.4.5. Europe Gene Therapy Market, by Therapy Area, 2016-2026 54
    • 5.4.5.1. Europe Gene Therapy Market, by Therapy Area, 2016-2026 (USD Million) 54
    • 5.4.6. Germany 55
    • 5.4.6.1. Germany Market size and forecast, 2016-2026 (USD Million) 55
    • 5.4.7. France 56
    • 5.4.7.1. France Market size and forecast, 2016-2026 (USD Million) 56
    • 5.4.8. U.K. 57
    • 5.4.8.1. U.K. Market size and forecast, 2016-2026 (USD Million) 57
    • 5.4.9. Italy 58
    • 5.4.9.1. Italy Market size and forecast, 2016-2026 (USD Million) 58
    • 5.4.10. Spain 59
    • 5.4.10.1. Spain Market size and forecast, 2016-2026 (USD Million) 59
    • 5.4.11. Nordic Countries 60
    • 5.4.11.1. Nordic Countries Market size and forecast, 2016-2026 (USD Million) 60
    • 5.4.12. Benelux Union 61
    • 5.4.12.1. Benelux Union Market size and forecast, 2016-2026 (USD Million) 61
    • 5.4.13. Rest of Europe 62
    • 5.4.13.1. Rest of Europe Market size and forecast, 2016-2026 (USD Million) 62
    • 5.5. Asia Pacific 63
    • 5.5.1. Asia Pacific Gene Therapy Market size and forecast, 2016-2026 63
    • 5.5.2. Asia Pacific Gene Therapy Market, by Country, 2018 & 2025 (USD Million) 63
    • 5.5.3. Asia Pacific Gene Therapy Market, by Type, 2016-2026 65
    • 5.5.3.1. Asia Pacific Gene Therapy Market, by Type, 2016-2026 (USD Million) 65
    • 5.5.4. Asia Pacific Gene Therapy Market, by Vector Type, 2016-2026 66
    • 5.5.4.1. Asia Pacific Gene Therapy Market, by Vector Type, 2016-2026 (USD Million) 66
    • 5.5.5. Asia Pacific Gene Therapy Market, by Therapy Area, 2016-2026 67
    • 5.5.5.1. Asia Pacific Gene Therapy Market, by Therapy Area, 2016-2026 (USD Million) 67
    • 5.5.6. China 68
    • 5.5.6.1. China Market size and forecast, 2016-2026 (USD Million) 68
    • 5.5.7. Japan 69
    • 5.5.7.1. Japan Market size and forecast, 2016-2026 (USD Million) 69
    • 5.5.8. India 70
    • 5.5.8.1. India Market size and forecast, 2016-2026 (USD Million) 70
    • 5.5.9. New Zealand 71
    • 5.5.9.1. New Zealand Market size and forecast, 2016-2026 (USD Million) 71
    • 5.5.10. Australia 72
    • 5.5.10.1. Australia Market size and forecast, 2016-2026 (USD Million) 72
    • 5.5.11. South  Korea 73
    • 5.5.11.1. South  Korea Market size and forecast, 2016-2026 (USD Million) 73
    • 5.5.12. South-East Asia 74
    • 5.5.12.1. South-East Asia Market size and forecast, 2016-2026 (USD Million) 74
    • 5.5.13. Rest of Asia Pacific 75
    • 5.5.13.1. Rest of Asia Pacific Market size and forecast, 2016-2026 (USD Million) 75
    • 5.6. Latin America 76
    • 5.6.1. Latin America Gene Therapy Market size and forecast, 2016-2026 76
    • 5.6.2. Latin America Gene Therapy Market, by Country, 2018 & 2025 (USD Million) 76
    • 5.6.3. Latin America Gene Therapy Market, by Type, 2016-2026 78
    • 5.6.3.1. Latin America Gene Therapy Market, by Type, 2016-2026 (USD Million) 78
    • 5.6.4. Latin America Gene Therapy Market, by Vector Type, 2016-2026 79
    • 5.6.4.1. Latin America Gene Therapy Market, by Vector Type, 2016-2026 (USD Million) 79
    • 5.6.5. Latin America Gene Therapy Market, by Therapy Area, 2016-2026 80
    • 5.6.5.1. Latin America Gene Therapy Market, by Therapy Area, 2016-2026 (USD Million) 80
    • 5.6.6. Brazil 81
    • 5.6.6.1. Brazil Market size and forecast, 2016-2026 (USD Million) 81
    • 5.6.7. Argentina 82
    • 5.6.7.1. Argentina Market size and forecast, 2016-2026 (USD Million) 82
    • 5.6.8. Rest of Latin America 83
    • 5.6.8.1. Rest of Latin America Market size and forecast, 2016-2026 (USD Million) 83
    • 5.7. The Middle-East and Africa 84
    • 5.7.1. The Middle-East and Africa Gene Therapy Market size and forecast, 2016-2026 84
    • 5.7.2. The Middle-East and Africa Gene Therapy Market, by Country, 2018 & 2025 (USD Million) 84
    • 5.7.3. The Middle-East and Africa Gene Therapy Market, by Type, 2016-2026 86
    • 5.7.3.1. The Middle-East and Africa Gene Therapy Market, by Type, 2016-2026 (USD Million) 86
    • 5.7.4. The Middle-East and Africa Gene Therapy Market, by Vector Type, 2016-2026 87
    • 5.7.4.1. The Middle-East and Africa Gene Therapy Market, by Vector Type, 2016-2026 (USD Million) 87
    • 5.7.5. The Middle-East and Africa Gene Therapy Market, by Therapy Area, 2016-2026 88
    • 5.7.5.1. The Middle-East and Africa Gene Therapy Market, by Therapy Area, 2016-2026 (USD Million) 88
    • 5.7.6. Saudi Arabia 89
    • 5.7.6.1. Saudi Arabia Market size and forecast, 2016-2026 (USD Million) 89
    • 5.7.7. UAE 90
    • 5.7.7.1. UAE Market size and forecast, 2016-2026 (USD Million) 90
    • 5.7.8. Egypt 91
    • 5.7.8.1. Egypt Market size and forecast, 2016-2026 (USD Million) 91
    • 5.7.9. Kuwait 92
    • 5.7.9.1. Kuwait Market size and forecast, 2016-2026 (USD Million) 92
    • 5.7.10. South Africa 93
    • 5.7.10.1. South Africa Market size and forecast, 2016-2026 (USD Million) 93
    • 5.7.11. Rest of Middle-East Africa 94
    • 5.7.11.1. Rest of Middle-East Africa Market size and forecast, 2016-2026 (USD Million) 94
  •  
  • CHAPTER 6. Gene Therapy market – Competitive Landscape 95
    • 6.1. Competitor Market Share – Revenue 95
    • 6.2. Market Concentration Rate Analysis, Top 3 and Top 5 Players 97
    • 6.3. Strategic Development 98
    • 6.3.1. Acquisitions and Mergers 98
    • 6.3.2. New Products 98
    • 6.3.3. Research & Development Activities 98
  •  
  • CHAPTER 7. Company Profiles 99
    • 7.1. Voyager Therapeutics, Inc. 99
    • 7.1.1. Company Overview 99
    • 7.1.2. Voyager Therapeutics, Inc. Revenue and Gross Margin 99
    • 7.1.3. Product portfolio 100
    • 7.1.4. Recent initiatives 101
    • 7.2. Spark Therapeutics, Inc. 101
    • 7.2.1. Company Overview 101
    • 7.2.2. Spark Therapeutics, Inc. Revenue and Gross Margin 101
    • 7.2.3. Product portfolio 102
    • 7.2.4. Recent initiatives 103
    • 7.3. Sangamo Therapeutics 103
    • 7.3.1. Company Overview 103
    • 7.3.2. Sangamo Therapeutics Revenue and Gross Margin 103
    • 7.3.3. Product portfolio 104
    • 7.3.4. Recent initiatives 105
    • 7.4. Human Stem Cells Institute PJSC 105
    • 7.4.1. Company Overview 105
    • 7.4.2. Human Stem Cells Institute PJSC Revenue and Gross Margin 105
    • 7.4.3. Product portfolio 106
    • 7.4.4. Recent initiatives 107
    • 7.5. Orchard Therapeutics plc 107
    • 7.5.1. Company Overview 107
    • 7.5.2. Orchard Therapeutics plc Revenue and Gross Margin 107
    • 7.5.3. Product portfolio 108
    • 7.5.4. Recent initiatives 109
    • 7.6. Genenta Science 109
    • 7.6.1. Company Overview 109
    • 7.6.2. Genenta Science Revenue and Gross Margin 109
    • 7.6.3. Product portfolio 110
    • 7.6.4. Recent initiatives 111
    • 7.7. Chiesi Farmaceutici S.p.A. 111
    • 7.7.1. Company Overview 111
    • 7.7.2. Chiesi Farmaceutici S.p.A. Revenue and Gross Margin 111
    • 7.7.3. Product portfolio 112
    • 7.7.4. Recent initiatives 113
    • 7.8. Novartis AG 113
    • 7.8.1. Company Overview 113
    • 7.8.2. Novartis AG Revenue and Gross Margin 113
    • 7.8.3. Product portfolio 114
    • 7.8.4. Recent initiatives 115
    • 7.9. GlaxoSmithKline PLC 115
    • 7.9.1. Company Overview 115
    • 7.9.2. GlaxoSmithKline PLC Revenue and Gross Margin 115
    • 7.9.3. Product portfolio 116
    • 7.9.4. Recent initiatives 117
    • 7.10. Gilead Sciences, Inc. 117
    • 7.10.1. Company Overview 117
    • 7.10.2. Gilead Sciences, Inc. Revenue and Gross Margin 117
    • 7.10.3. Product portfolio 118
    • 7.10.4. Recent initiatives 119
    • 7.11. Bristol - Myers Squibb Delta Company Limited 119
    • 7.11.1. Company Overview 119
    • 7.11.2. Bristol - Myers Squibb Delta Company Limited Revenue and Gross Margin 119
    • 7.11.3. Product portfolio 120
    • 7.11.4. Recent initiatives 121
    • 7.12. Advanced Cell & Gene Therapy, LLC 121
    • 7.12.1. Company Overview 121
    • 7.12.2. Advanced Cell & Gene Therapy, LLC Revenue and Gross Margin 121
    • 7.12.3. Product portfolio 122
    • 7.12.4. Recent initiatives 123
    • 7.13. Applied Genetic Technologies Corporation (AGTC) 123
    • 7.13.1. Company Overview 123
    • 7.13.2. Applied Genetic Technologies Corporation (AGTC) Revenue and Gross Margin 123
    • 7.13.3. Product portfolio 124
    • 7.13.4. Recent initiatives 125
    • 7.14. Audentes Therapeutics, Inc. 125
    • 7.14.1. Company Overview 125
    • 7.14.2. Audentes Therapeutics, Inc. Revenue and Gross Margin 125
    • 7.14.3. Product portfolio 126
    • 7.14.4. Recent initiatives 127
    • 7.15. Benitec Biopharma 127
    • 7.15.1. Company Overview 127
    • 7.15.2. Benitec Biopharma Revenue and Gross Margin 127
    • 7.15.3. Product portfolio 128
    • 7.15.4. Recent initiatives 129
    • 7.16. Biogen 129
    • 7.16.1. Company Overview 129
    • 7.16.2. Biogen Revenue and Gross Margin 129
    • 7.16.3. Product portfolio 130
    • 7.16.4. Recent initiatives 131
    • 7.17. Bluebird bio, Inc. 131
    • 7.17.1. Company Overview 131
    • 7.17.2. Bluebird bio, Inc. Revenue and Gross Margin 131
    • 7.17.3. Product portfolio 132
    • 7.17.4. Recent initiatives 133
    • 7.18. Genzyme Corporation 133
    • 7.18.1. Company Overview 133
    • 7.18.2. Genzyme Corporation Revenue and Gross Margin 133
    • 7.18.3. Product portfolio 134
    • 7.18.4. Recent initiatives 135
    • 7.19. Eurofins Genomics 135
    • 7.19.1. Company Overview 135
    • 7.19.2. Eurofins Genomics Revenue and Gross Margin 135
    • 7.19.3. Product portfolio 136
    • 7.19.4. Recent initiatives 137
    • 7.20. Pfizer Inc. 137
    • 7.20.1. Company Overview 137
    • 7.20.2. Pfizer Inc. Revenue and Gross Margin 137
    • 7.20.3. Product portfolio 138
    • 7.20.4. Recent initiatives 139
  •  
  • CHAPTER 8. Gene Therapy — Industry Analysis 140
    • 8.1. Gene Therapy Market – Key Trends 140
    • 8.1.1. Market Drivers 141
    • 8.1.2. Market Restraints 141
    • 8.1.3. Market Opportunities 142
    • 8.2. Value Chain Analysis 143
    • 8.3. Technology Roadmap and Timeline 144
    • 8.4. Gene Therapy Market – Attractiveness Analysis 145
    • 8.4.1. By Type 145
    • 8.4.2. By Vector Type 145
    • 8.4.3. By Therapy Area 146
    • 8.4.4. By Region 148
    • CHAPTER 9. Marketing Strategy Analysis, Distributors 149
    • 9.1. Marketing Channel 149
    • 9.2. Direct Marketing 150
    • 9.3. Indirect Marketing 150
    • 9.4. Marketing Channel Development Trend 150
    • 9.5. Economic/Political Environmental Change 151
  •  
  • CHAPTER 10. Report Conclusion 152
  •  
  • CHAPTER 11. Research Approach & Methodology 153
    • 11.1. Report Description 153
    • 11.2. Research Scope 154
    • 11.3. Research Methodology 154
    • 11.3.1. Secondary Research 155
    • 11.3.2. Primary Research 156
    • 11.3.3. Models 157
    • 11.3.3.1. Company Share Analysis Model 157
    • 11.3.3.2. Revenue Based Modeling 158
    • 11.3.3.3. Research Limitations 158

Safe and Secure SSL Encrypted

Choose License Type

INQUIRY FOR BUYING

REQUEST FOR SAMPLE

icon
icon
icon
icon
icon
icon
icon
icon

INQUIRY FOR BUYING

icon
icon
icon
icon
icon
icon
icon
icon
Explore Your Business Market